First, this study was a stratified analysis to investigate the effectiveness of antiplatelet agents for the secondary prevention of stroke according to CYP2C19 genotypes on the basis of our previous randomized-controlled trial [18]. The gene discussed is CYP2C19; the disease is Stroke.